Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Branaplam in Infants with Type 1 SMA
NCT02268552Phase 2Completed
- Sponsor
- Novartis
- Start
- Apr 2015
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 7
01
Overview
A Phase 2 trial of branaplam in spinal muscular atrophy type 1, sponsored by Novartis. Started Apr 2015; status: completed.
02
Drugs
branaplam
03
Conditions
spinal muscular atrophy type 1
Beyond the preview
Go deeper on NCT02268552.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02268552.